Fenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.
Fenghuang Zhan, MD, PhD
Advertisement
Articles by Fenghuang Zhan, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
3
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
4
VIR-5500 Receives FDA Fast Track Designation in mCRPC
5